We developed a liposome-intercalated preparation of amphotericin B by using small, unilamellar vesicles 0.06 to 0.1 gim in diameter. In contrast to previously described liposomal preparations of amphotericin B, these vesicles have the advantage that they are small enough to be filter sterilized. We compared the efficacy of liposomal amphotericin B with that of the commercial drug given as an intravenous bolus every other day for 13 days (seven doses) in mice with disseminated candidiasis. Survival rates were similar for the two preparations at each dosage of amphotericin B; however, the highest survival rates occurred at dosages of liposomal amphotericin B which would be lethal to these animals if administered as the commercial drug. Viable colony counts of fungi in various organs, particularly the kidneys, tended to be lower with increasing dosage of the drug. However, some organisms persisted even after 13 days. These studies indicate that liposomal formulations of amphotericin B merit further investigation because of their improved therapeutic margins.
Although amphotericin B is the most effective agent available for the treatment of many systemic fungal infections, its use is frequently complicated by serious adverse reactions (3, 5, 9) . Attempts to circumvent the toxicity of amphotericin B by using the methyl ester at first appeared promising but were followed by reports that this formulation might cause leukoencephalopathy (4) . Suggestions that the coadministration of mannitol might reduce the nephrotoxic potential of amphotericin B could not be substantiated (2) .
Incorporation of amphotericin B into liposomes offers a potential means to reduce the toxicity of this antifungal drug.
Two groups have reported marked reductions in the acute lethality of liposome-intercalated amphotericin B and improved survival in murine models of histoplasmosis (12) , cryptococcosis (6) , and disseminated candidiasis (7) , presumably because higher doses can be tolerated. However, both groups used relatively large multilamellar liposomes, leading to the possibility of embolization to organs, particularly lungs (12) .
We have developed a liposomal preparation of amphotericin B consisting of small, unilamellar vesicles with a size range of 0.06 to 0.1 ,um. The acute 50% lethal dose (LD50) of this liposomal amphotericin B preparation given as an intravenous bolus to mice is 11.8 mg/kg, compared with 2.3 mg/kg for commercial amphotericin B. One-half to three-quarters of the LD50 can be administered every third day to mice for at least 2 weeks without adverse effects (unpublished data). The present paper reports the activity of this liposomal preparation of amphotericin B in mice with disseminated candidiasis.
MATERIALS AND METHODS Drug preparations. Amphotericin B was obtained from The Squibb Institute, Princeton, N.J., as the commercial preparation containing sodium desoxycholate.
Small unilamellar vesicles were prepared by sonication in a bath-type sonicator (11) from a lipid composition of egg phosphatidylcholine (Avanti Polar Lipids, Birmingham, Ala.), cholesterol, and tocopherol succinate (Sigma Chemical Co., St. Louis, Mo.) in a molar ratio of 5:3:1. The lipids, dissolved in chloroform, were deposited on the sides of a round-bottom flask by evaporation of the solvent. A solution of amphotericin B (Sigma) in dimethyl sulfoxide (25 mg/ml) was added to the dried lipids (0.2 ml of dimethyl sulfoxide solution to 50 ,umol of total lipid) to give a molar ratio of amphotericin B to total lipid of 10%. This corresponds to a ratio of 5 mg of amphotericin B to 31.3 mg of total lipid. Phosphate-buffered saline (PBS) (137 mM NaCl, 2.5 mM KCI, 6.4 mM Na2HPO4 [pH 7.4]) was added to the flask to rehydrate the lipids and to give a final lipid concentration of 31.3 mg/ml.
The dispersion was hydrated under nitrogen for 10 min and then sonicated under nitrogen for 60 min at room temperature. The slightly opalescent yellow preparation was dialyzed at 4°C against 200 volumes of PBS, which was changed two times over a 24-h period to remove nonintercalated amphotericin B and dimethyl sulfoxide. A typical preparation retained 70% of the initial amphotericin B (3,000 ,ug of amphotericin B per 31.3 mg of total lipid per ml). The liposomes were sterilized by filtration through a sterile 0.22-,um filter (Millipore Corp., Bedford, Mass.) into a sterile container.
The drug concentration in the liposome dispersion was determined by diluting a sample of the final preparation 1/1,000 in methanol, measuring the absorbance at 388 and 406 nm, and comparing the absorbance with a standard I curve prepared from solid amphotericin diluted in methanol.
The standard curve was linear up to 6 p.g of amphotericin B
per ml. Three preparations were used in the course of this study. The preparation used for the first efficacy experiment I (see below) contained 3,500 ,ug of amphotericin B per ml; the I preparations used for the second and third efficacy experiments contained 2,850 and 2,560 ,ug of amphotericin B per I ml, respectively. The preparation used in the study of tissue colony counts contained 2,560 ,ug of amphotericin B per ml. Efficacy studies. Mice were infected on day zero by intravenous injection of C. albicans. Twenty-four hours later they were randomly divided into groups which were allocated to receive one of the following intravenous regimens: amphotericin B in a dosage of 0.5, 1.0, or 1.5 mg/kg or liposomal amphotericin B in a dosage of 0.5, 1.0, 1.5, 2.5, or 5.0 mg/kg. In two experiments, an additional group received liposomal amphotericin B at 3.75 mg/kg. Randomly chosen control animals were given intravenous PBS or "empty" liposomes; the latter had the same quantity of liposomes as the preparation containing amphotericin B (5.0 mg/kg) but without the antifungal drug. The injection volume was 0.1 ml in all instances. The injections were administered over about 5 s into the tail vein beginning on day 1 and were repeated every other day for seven doses (i.e., through day 13). Survival was recorded every morning during treatment and for 12 days after the last dose, i.e., until day 25.
Tissue colony counts. The numbers of viable fungi in the major organs during treatment were determined as follows. Animals treated with the protocol described above were killed in groups of two to four animals 1 day (20 to 24 h) after the first dose (day 2), 1 CFU, resulted in infection localized to the kidneys, with almost no mortality. Larger inocula, e.g., 6 x 106 to 7 x 106 CFU, produced almost uniform mortality within a few days, even in animals treated with amphotericin B.
We noted an apparent increase in the virulence of the fungus as the months elapsed. Thus, for later experiments, inocula of 3 x 106 to 3.5 x 106 CFU produced the desired 80 to 90% mortality within 2 weeks in control animals. The reason for the change is not clear. We continued to use mice of the same strain and age, from the same supplier. We did not use in vivo passage but maintained the fungus on agar plates, transferring it to a new plate every few days. The MIC and MFC of amphotericin B and liposomal amphotericin B for the organisms remained unchanged.
Most of the deaths in animals treated with amphotericin B or liposomal amphotericin B occurred between the days 3 and 6 after infection. Deaths in control animals given PBS or empty liposomes occurred throughout the period of observation; the median time to death in the first experiment (see below) was 4 days.
Effect on survival. Table 1 shows the results of three experiments in which amphotericin B or liposomal ampho- tericin B was administered in various dosages every other day for seven doses, beginning 1 day after infection. There were 21 mice per group in experiment 1, except that only 8 mice were given empty liposomes. There were 8 mice per group in experiment 2 and 10 mice per group in experiment 3. The mortality in each group on day 25, i.e., 12 days after the last dose of drug, is indicated. In a few instances animals were dropped from the study when there was a question as to whether some portion of a treatment dose extravasated.
In the first experiment the infecting inoculum contained 5 x 106 CFU. The survival rates for control animals given PBS or empty liposomes were 4.7 and 12.5%, respectively; in contrast, the rates for animals given commercial amphotericin B in doses of 0.5 to 1.5 mg/kg per injection ranged from 36.8 to 50%. Higher doses of amphotericin B were not given because the LD50 of the drug is 2.3 mg/kg in our laboratory (unpublished data). When liposomal amphotericin B was given in the same dosages as the commercial amphotericin B, the survival rates were comparable (47.3 to 52.3%). However, at a dosage of 2.5 mg/kg, the survival rate with the liposomal preparation was 84.2%; this was significantly better (P < 0.03; two-sample t-test) than the survival rate with any nonliposomal regimen. The survival rate with liposomal amphotericin B was lower at 5 mg/kg than at 2.5 mg/kg. The median time of survival for mice that died was similar for control groups and animals given any form of amphotericin B, i.e., 3 to 5 days.
The infecting inoculum in the second trial in Table 1 was 5.5 x 106 CFU per ml. The only survivors were animals given 2.5 mg or more of liposomal amphotericin B per kg. The survival rate was again slightly (but not significantly) better at 2.5 mg/kg than with higher dosages. The median time of survival and the range were similar for groups given amphotericin B in any form and control groups in the second experiment. Because of the increased virulence of the organism which became evident during the second experiment, we reexamined the dose-response curve for the infection and administered 3.7 x 106 fungi in the third trial. In this instance, the best results were produced by liposomal amphotericin B in a dosage of 5 mg/kg (60% survival), and although the groups were small, there appeared to be a more linear dose-response curve with the liposomal preparation in this experiment than in the previous ones.
Effect on colony counts in tissues. On macroscopic examination, the kidneys of control (PBS-treated) mice were found to have pinpoint cortical abscesses during week There was a rough correlation between the decrease in renal colony counts and the dosage of drug as well as the number of doses given.
The effects of treatment on the number of viable colonies in the liver, spleen, and lungs were less striking than in the kidneys. This may relate to the fact that fungal counts in these organs declined spontaneously with time even in PBStreated controls. Nonetheless, there appeared to be a relationship between the dosage of amphotericin B or liposomal amphotericin B and colony counts in the liver, spleen, and lung.
Viable organisms could be detected in the liver and kidneys of some animals even after seven doses of the drug (Table 2 ). The MIC and MFC of these isolates were determined and were found to be identical with those of the original infecting strain, indicating that there had been no selection of resistant subpopulations. DISCUSSION Liposome-intercalated amphotericin B produced higher survival rates than commercial amphotericin B in each of three trials (Table 1) . At comparable dosages, survival rates with the two liposomal formulations were similar, and empty liposomes had no apparent effect on survival. Thus, the main benefit of the liposomal formulation probably lies in the fact that much higher dosages of amphotericin B can be tolerated in this form. Repeated trials in our laboratory with CD-1 and Swiss-Webster mice have shown that the LD50 of commer- The highest survival rates in this study were always obtained with a high-dose liposomal preparation. However, the dose-response curves were not linear and sometimes fell off at high doses of the drug, although these were well below the acute LD50 in healthy mice. Previous experiments in our laboratory (unpublished data) have indicated that up to three-quarters of the acute LD50 could be administered every third day to mice for 2 weeks without apparent adverse effects. It may be that animals that are sick because of infection are more susceptible to the toxic effects of amphotericin B than are healthy animals.
The results of this study are in general agreement with data reported by other workers who found an improved therapeutic index when liposomal preparations of amphotericin B were used in mice with acute cryptococcosis, histoplasmosis, and candidiasis (6, 7, 12) . Two of those studies (6, 12) were done with sterol-containing multilamellar vesicles (8, 10) , which reduced the acute lethality of amphotericin B by ninefold. The third study used nonsterolic multilamellar vesicles, which reduced the acute toxicity of amphotericin B by more than 12-fold (7). However, when we prepared and administered vesicles of the type described by Lopez-Berestein et al. (7), the reduction in toxicity was not as great as that achieved with our own preparation (unpublished data). Small unilamellar vesicles such as we have prepared have the benefit that they can be sterilized by passage through a 0.22-pum filter and are less likely to be retained in the lung. Larger vesicles may exhibit marked trapping in the lung (12) .
The reasons for the decreased toxicity of liposomal amphotericin B are not clear but may relate to a reduction in the interaction of intercalated (1) drug with susceptible host membranes. Ultimately, the greater affinity of amphotericin B for fungal ergosterol than for the cholesterol of animal cell membranes enables the drug to attach to the fungus. It has been suggested that incorporation into ergosterol-containing liposomes may impair the antifungal activity of amphotericin B; however, we observed no major effect of this kind with various formulations studied in vitro (unpublished data). In any event, the preparation used in the present experiments contains cholesterol rather than ergosterol, a plant sterol that might induce toxic effects when injected into animals.
The potential advantage of the liposomal preparation clearly rests on its lower toxicity when administered by rapid intravenous injection (6, 7, 12) . Whether toxicity will be less under conditions of clinical use, in which much slower infusions are used, remains to be determined. Further studies are needed to establish the precise nature of the toxicity and the blood levels achieved by the commercial and liposomal preparations.
It was of interest that there were viable fungi in the kidneys and liver as long as 14 days after infection, even in animals treated with high dosages of drug. The reasons for the persistence of these organisms are not known. Their susceptibility to amphotericin B or liposomal amphotericin B remained identical to that of the original infecting strain. The observation emphasizes the importance of prolonged treatment of disseminated Candida infection.
These studies and those reported by others (6, 7, 12) suggest that liposomal formulations may be of considerable value in the administration of amphotericin B. Further work is needed to perfect a pharmaceutically acceptable formulation that is optimal in terms of efficacy and toxicity.
